Compare GSK plc (GSK) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Neurocrine Biosciences Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: GSK plc is far larger — about 6.4× Neurocrine Biosciences Inc's market cap, and GSK plc pays a 3.9% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GSK | NBIX | |
|---|---|---|
Market Cap | $91.88B | $14.36B |
Volume | 7,730,529 | 1,237,180 |
Sector | Health | Health |
52-Week High | $61.18 | $185.50 |
52-Week Low | $43.24 | $123.10 |
Typical Hold Time | 93 Days | 23 Days |
Enterprise Value | $111.88B | $14.37B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
